MedTrace Logo

Pilot Trial for Treatment of Recurrent Glioblastoma

NCT05432518 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-04-25

No results posted yet for this study

Summary

This will be a single-arm open-label prospective pilot feasibility trial recruiting 10 adult patients with recurrent glioblastoma who are assigned to receive the personalized study treatment based on the genetic profile of their recurrent GBM tumor resected at the time of surgery. It will be aimed to gather preliminary information on the study intervention and the feasibility of conducting a full-scale trial.

Conditions

Interventions

DRUG

Afatinib

Afatinib will be administered orally at a dose of 40 mg daily in patients with EGFR amplification.

DRUG

Dasatinib

Dasatinib will be administered orally at a dose of 100 mg once daily in patients with PDGFR amplification.

DRUG

Palbociclib

Palbociclib will be administered orally at a dose of 125 mg once daily in patients with CDK4 and CDK6 amplification.

DRUG

Everolimus

Everolimus will be administered orally at a dose of 10 mg daily in patients with PI3K/PTEN/mTOR activated pathways.

DRUG

Olaparib

Olaparib will be administered orally at a dose of 300 mg twice daily in patients with TP53 mutation.

Sponsors & Collaborators

  • Tom Baker Cancer Centre

    collaborator OTHER

  • AHS Cancer Control Alberta

    lead OTHER

Principal Investigators

  • Paula de Robles · Arthur J.E. Child Comprehensive Cancer Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-27
Primary Completion
2027-07-01
Completion
2027-12-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05432518 on ClinicalTrials.gov